// App-Quantinova.ai

1287 : The dual IAP antagonist, ASTX660, increases the anti-tumor activity of paclitaxel in preclinical models of triple-negative breast cancer in vivo

Researchers

Presenter

  • Tomoko Smyth

Principal Investigators

  • Yoko Nakatsuru

  • Ryoto Fujita

  • George Ward

  • Luke Bevan

  • Jon Lewis

  • Nicola Wallis

  • John Lyons

Medical Centers

  • Astex Pharmaceutical, Inc., Cambridge, United Kingdom.

  • Taiho Pharmaceuticals, Tsukuba, Japan.

Locations

  • United Kingdom

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Solid malignancies

  • Breast cancer

  • Lymphomas

Biomarkers

  • Cluster of Differentiation 47

  • Tumor necrosis factor

  • X-linked inhibitor of apoptosis

Drug/Treatment

  • Paclitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved